Detalhe da pesquisa
1.
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Nature
; 596(7870): 126-132, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290408
2.
Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Nature
; 579(7798): 284-290, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103175
3.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
N Engl J Med
; 386(21): 1973-1985, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403841
4.
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
Oncologist
; 29(4): 342-349, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38207008
5.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Future Oncol
; 19(8): 549-557, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815433
6.
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Oncologist
; 27(11): 971-981, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972337
7.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
8.
Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review.
Ann Hematol
; 101(1): 1-10, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34962580
9.
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Nature
; 598(7881): E1, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34608287
10.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
N Engl J Med
; 378(21): 1976-1986, 2018 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658848
11.
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
Ann Rheum Dis
; 79(3): 332-338, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31540935
12.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 375(19): 1823-1833, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718847
13.
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.
J Natl Compr Canc Netw
; 17(6): 712-720, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200355
14.
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(7): 859-865, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487223
15.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
16.
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
Curr Treat Options Oncol
; 19(9): 46, 2018 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30101402
17.
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Lancet Oncol
; 18(12): 1600-1609, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29129441
18.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932067
19.
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Ann Rheum Dis
; 76(1): 43-50, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27307501
20.
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Kidney Int
; 90(3): 638-47, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27282937